# Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

> **NCT01910610** · PHASE3 · UNKNOWN · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 464 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **BIOLOGICAL:** FOLFIRI-cetuximab
- **BIOLOGICAL:** mFOLFOX6-bevacizumab
- **BIOLOGICAL:** OPTIMOX-bevacizumab
- **BIOLOGICAL:** irinotecan-based chemo + bevacizumab
- **BIOLOGICAL:** Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)
- **BIOLOGICAL:** XELOX + bevacizumab

## Key facts

- **NCT ID:** NCT01910610
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10-30
- **Primary completion:** 2023-07-13
- **Final completion:** 2024-12
- **Target enrollment:** 464 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910610, "Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01910610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*